Arda Ural

Arda Ural, PhD leads EY's Life Sciences and Healthcare business across the Americas. Dr. Ural has a proven track record in running businesses in pharma, biotech and med-tech industries with two decades of experience in general management, commercialization, product development, corporate strategy and M&A. He has demonstrated leadership in major brand management at Pfizer (US Team Leader Celebrex, Global Marketing Director Viagra), start-up and IPO experience at biotech (Eyetech / acquired by OSI/Astellas) and business turn-around in disposable medical devices (Becton Dickinson).
His board memberships include:
- Co-chair of BioNJ C-Suite Summit
- Chairman of BIO International Business Development and Finance Committee
- Member of BIO International Value, Patient Access and Reimbursement Committee
- Member BioNJ Business Development Executive Committee, Finance Committee and BioPartnering Program
- Board Member New Jersey Institute of Technology (NJIT) Business Advisory Board
- Board Member of In Vivo Editorial Advisory Board
- Former Member Program Committee at Advamed / MedTech Conference
- Former Member Board of Trustees of Brooklyn-Queens Conservatory of Music
Speaking In
11:00 AM - 12:00 PM
Tuesday, June 6
The 33rd edition of EY’s Beyond Borders Biotechnology Report offers a chance to take stock of the…